Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May 7;130(18):5860-1.
doi: 10.1021/ja801008m. Epub 2008 Apr 15.

Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants

Affiliations

Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants

Kai Deng et al. J Am Chem Soc. .

Abstract

QS-7-Api is an exceedingly potent immuno-adjuvant isolated from the bark of Quillaja saponaria. It is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccine clinical trials. Tedious isolation/purification protocols and uncertainty in its structural constitution have hindered the clinical development of QS-7. A chemical synthesis of QS-7-Api is described, providing structural verification of the adjuvant. A novel semisynthetic sequence to QS-7-Api has also been established, greatly facilitating access to QS-7 for preclinical and clinical evaluation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scheme 1<sup>a</sup>
Scheme 1a
a Reagents and conditions: (a) TIPSOTf, 2,6-lutidine, CH2Cl2, 0→23 °C, 96%; (b) H2, Pd–C, MeOH, 23 °C, 98%; (c) n-Bu2SnO, PhMe, reflux; CsF; PMBCl, DMF, 23 °C, 56%; (d) TBSCl, imidazole, DMAP, CH2Cl2, 23 °C, 97%; (e) Ac2O, Et3N, DMAP, CH2Cl2, 23 °C, >99%; (f) DDQ, MeOH, H2O, 0→23 °C, 86%.
Scheme 2<sup>a</sup>
Scheme 2a
a Reagents and conditions: (a) Ph2SO, Tf2O, TBP, CH2Cl2, −78→23 °C, 84%; (b) TBAF, THF, 0→23 °C, 95%; (c) Et2Zn, Pd(PPh3)4, Et2O, 23 °C; 68%; (d) TIPSCl, imidazole, DMAP, DMF, 23 °C, 75%; (e) Ph2SO, Tf2O, TBP, CH2Cl2, −78→23 °C, 75%; (f) 4, TBSOTf, CH2Cl2, 0 °C, 86%; (g) K2CO3, H2O, MeOH, 23 °C; (h) PhCH(OMe)2, p-TsOH, 23 °C, 94% (two steps); (i) p-TsOH, H2O, MeOH, 23 °C, 71%; (j) BnBr, Bu4NBr, NaOH, H2O, CH2Cl2, 23 °C, 84%; (k) 3, TMSOTf, Et2O, −45 °C, 86%; (l) DIBAL-H, CH2Cl2, −78 °C, 92%; (m) TESOTf, 2,6-lutidine, CH2Cl2, 0→23 °C, 99%; (n) TBAF, THF, 0 °C, >99%; (o) CCl3CN, DBU, CH2Cl2, 0 °C, 92%; (p) TMSOTf, 4Å ms, CH2Cl2, −15 °C, 62%; (q) TBAF, THF, 0 °C; (r) CCl3CN, DBU, CH2Cl2, 0→23 °C, 84% (two steps).
Scheme 3<sup>a</sup>
Scheme 3a
a Reagents and conditions: (a) 16, BF3·OEt2, 4Å ms, CH2Cl2, −78→23 °C, 71%; (b) TFA, H2O, CH2Cl2, 0 °C; H2, Pd–C, EtOH, THF, 23 °C, 71%; (c) KOH, EtOH, H2O, 80 °C; (d) TESOTf, Py, 40 °C; (e) CbzCl, Py, TBP, CH2Cl2, 23 °C, 68%; (f) 16, BF3·OEt2, 4Å ms, CH2Cl2, −78→23 °C, 80%; (g) H2, Pd–C, EtOH, THF, 23 °C; TFA, H2O, 0 °C, 77%.

Similar articles

Cited by

References

    1. Kensil CR, Patel U, Lennick M, Marciani D. J Immunol. 1991;146:431–437. - PubMed
    1. Soltysik S, Wu JY, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, Kensil CR. Vaccine. 1995;13:1403–1410. - PubMed
    1. Kensil CR. Crit Rev Ther Drug Carrier Syst. 1996;13:1–55. - PubMed
    1. Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO. Vaccine. 2000;18:597–603. - PubMed
    1. Livingston PO, Ragupathi G. Hum Vaccines. 2006;2:137–143. - PubMed

Publication types

MeSH terms